Drug resistance and recurrence are the major obstacles to
bladder cancer chemotherapy. Our laboratory had reported that nucleophosmin1 was one of the differentially expressed
proteins between
bladder cancer cell lines PUMC-91 and PUMC-91/1.0ADM based on 2D-PAGE proteomics approaches. In this study, we want to explore the relationship among nucleophosmin1, drug resistance, and recurrence of
bladder cancer, using normal bladder epithelia cell line SV-HUC-1,
bladder cancer cell lines PUMC-91, PUMC-91 against gradient doses of
adriamycin (0.3, 0.6, and 1.0 μg/ml), and
bladder cancer tissue samples. The
bladder cancer tissue samples were divided into two groups according to the interval of recurrence (<6 months and >2 years). The differences were detected by Western blotting and immunohistochemistry. The
protein of nucleophosmin1 was differentially expressed with each other in SV-HUC-1, PUMC-91, PUMC-91/0.3ADM, and PUMC-91/1.0ADM (p < 0.05). Nucleophosmin1 was less expressed in later recurring (>2 years)
bladder cancer tissue samples compared with samples that recurred <6 months (p = 0.035). The expression of nucleophosmin1 was independently associated with gradient drug resistance and recurrent frequency of
bladder cancer. Nucleophosmin1 was a key regulator in either a
drug-resistant
bladder cancer or
bladder cancer recurrence model. It may be possible to think nucleophosmin1 can provide more helpful information for clinical
drug treatment of
bladder cancer patients and frequently recurred ones.